Back to top

vaccines: Archive

Zacks Equity Research

Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook

Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook

Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.

MRKNegative Net Change GILDNegative Net Change MRNANegative Net Change

Zacks Equity Research

GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment

GSKNegative Net Change JNJNegative Net Change PFENegative Net Change HLNNegative Net Change